pharma · Hemorrhoids · Persistent or Recurrent Cutaneous T-Cell Lymphoma · CTOR
CITIUS ONCOLOGY
CITIUS ONCOLOGY, INC.
Citius Oncology is a pharma organization headquartered in Cranford, USA. It trades on NYSE under ticker CTOR. Primary therapeutic focus areas include Hemorrhoids, Persistent or Recurrent Cutaneous T-Cell Lymphoma. NovaPh
Cranford, USA HQ
2024 Founded
5 Employees
Public company Type
CTOR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cranford, USA
- Founded
- 2024
- Employees
- 5
- Programs
- 3
- Drugs
- 8
- Patents
- 0
E7777 9 mcg/kg
Phase 3 · small molecule · Persistent or Recurrent Cutaneous T-Cell Lymphoma
E7777 9 mcg/kg for Persistent or Recurrent Cutaneous T-Cell Lymphoma is a Phase 3 program (small_molecule) at CITIUS ONCOLOGY, INC. with 1 ClinicalTrials.gov record(s).
Internal code E7777-G000-302
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CITIUS ONCOLOGY, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Persistent or Recurrent Cutaneous T-Cell Lymphoma
- Status
- completed
- Trials
- 1